(Q51368655)

4 April 2018

title

Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. (English)

1 reference

4 April 2018

polycystic ovary syndrome

main subject

obesity

0 references

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

based on heuristic

inferred from title

cardiovascular disease in women

0 references

1 reference

2

1 reference

4 April 2018

author name string

L F N Zueff

series ordinal

1

1 reference

4 April 2018

C S Vieira

series ordinal

3

1 reference

4 April 2018

R A Ferriani

series ordinal

4

1 reference

4 April 2018

publication date

9 February 2012

1 reference

4 April 2018

Ultrasound in Obstetrics and Gynecology

published in

1 reference

4 April 2018

volume

39

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

page(s)

341-347

1 reference

4 April 2018

The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus

cites work

1 reference

The prevalence and features of the polycystic ovary syndrome in an unselected population

21 January 2018

1 reference

The pathophysiology of polycystic ovary syndrome

21 January 2018

1 reference

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

Ovarian hyperstimulation syndrome: pathophysiology and prevention

21 January 2018

1 reference

Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters

21 January 2018

1 reference

Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease

21 January 2018

1 reference

Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome

21 January 2018

1 reference

Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome

21 January 2018

1 reference

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?

21 January 2018

1 reference

Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients

21 January 2018

1 reference

Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin

21 January 2018

1 reference

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism

21 January 2018

1 reference

Sonographic evaluation of endothelial function in letrozole and tamoxifen users

21 January 2018

1 reference

Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women

21 January 2018

1 reference

Brachial artery pulsatility index change 1 minute after 5-minute forearm compression: comparison with flow-mediated dilatation

21 January 2018

1 reference

New assessment of endothelium-dependent flow-mediated vasodilation to characterize endothelium dysfunction.

21 January 2018

1 reference

Imaging-based quantification of hepatic fat: methods and clinical applications

21 January 2018

1 reference

Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool?

21 January 2018

1 reference

Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response

21 January 2018

1 reference

Expert consensus document on arterial stiffness: methodological issues and clinical applications

21 January 2018

1 reference

Non-alcoholic fatty liver: another feature of the metabolicsyndrome?

21 January 2018

1 reference

Hepatocellular carcinoma in the non-cirrhotic liver

21 January 2018

1 reference

Hormonal contraception and risk of cancer.

21 January 2018

1 reference

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters

21 January 2018

1 reference

The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deteriora

21 January 2018

1 reference

Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome?

21 January 2018

1 reference

Dissociation of endothelial function and arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.

21 January 2018

1 reference

Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.

21 January 2018

1 reference

A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/UOG.10084

1 reference

4 April 2018

1 reference

4 April 2018